ClinicalTrials.gg
CompletedNCT00448435Updated Jun 8, 2010Results posted

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

A Phase 3 interventional study of GW815SF HFA MDI and salmeterol and fluticasone propionate in Bronchial Asthma, sponsored by GlaxoSmithKline. Completed at 8 sites in Japan. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2010-06-08.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
5 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.

Enrollment
29th of 46
51 · median 128
Started
2007
with 7 others
Phase 3
6 of 46
none open now
Registered
21st of 46
by date
Lead sponsor
22 of 46
GlaxoSmithKline

Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 29th largest by enrollment, is one of 8 that started in 2007, is one of 6 in phase 3, and was the 21st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →

About Salmeterol Xinafoate

Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies testing Salmeterol Xinafoate in Asthma as a file.
02

Study summary

To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid in paediatric patients with asthma.

To evaluate the safety of long-term treatment of GW815SF HFA MDI 25/50µg 1 inhalation bid in paediatric patients with asthma.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

Keywords

  • Salmeterol
  • Fluticasone propionate
  • Salmeterol/Fluticasone propionate combination
  • Pediatric bronchial asthma
04

Who can participate

Ages eligible
5 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Inclusion Criteria for Entry in Run-in Period

A pediatric patient already diagnosed as having bronchial asthma who meets all of the following criteria is eligible for the study:

  • Male or female patients aged ≥5 and ≤14 years. Enrolment of a female patient of is allowed only if she is tested negative in the pregnancy testing at the start of Treatment Period 1 and if she agrees to undergo pregnancy testing at the protocol-specified timings and to take measures without fail.
  • Written must be obtained from a legally acceptable representative of the subject. Consent of the subject him/herself should also be obtained, wherever possible, after giving an explanation in an as easy to understand as possible manner.
  • An outpatient who has been treated with ICS (FP 100μg/day or equivalent) for at least 4 weeks prior to Visit 1.
  • Able to use a peak flow meter in a correct manner in the investigator's/subinvestigator's judgment.
  • Able to use MDI and DPI in a correct manner (with the assistance of his/her caregiver as necessary) in the investigator's/subinvestigator's judgment.

Inclusion Criteria for Entry in Treatment Period 1 A subject will be randomized to one of the two treatment groups only if he/she has completed the run-in period and meets all the following criteria.

  1. Has a mean of morning PEF measurements in the last 7 days of the run-in period (excluding the first day of Treatment Period 1) ≤90% of his/her best PEF measurement .
  2. Was able to perform entry in the asthma diary and PEF measurements in a correct manner in the investigator's/subinvestigator's judgment.
  3. Able to use MDI and DPI in a correct manner (with the assistance of his/her caregiver as necessary) in the investigator's/subinvestigator's judgment.

Exclusion criteria:

  • Exclusion Criteria for Entry in Run-in Period

A patient who applies any of the following criteria is not eligible for the study:

  • Admitted to the hospital due to asthma exacerbation within 8 weeks prior to Visit 1.
  • Used systemic within 4 weeks prior to Visit 1.
  • Received antibacterials or antivirals for treatment of upper or lower respiratory tract infection within 2 weeks prior to Visit 1.
  • Has a safety problem in participation in the study because of a serious, uncontrolled systemic disease including nervous system disorder.
  • Has or is suspected to have deep-seated mycosis or infection to which no effective antibacterial agent is available.
  • Has or is suspected to have to the product, rescue medication or any ingredients of them.
  • Is pregnant or lactating, may be pregnant, or plans for pregnancy during the study period.
  • Has received the last dose in another clinical study within 2 months prior to this study.
  • Is not eligible for the study in the investigator's/subinvestigator's judgment.

Exclusion Criteria for Entry in Treatment Period 1

Enrolment of a subject completing the run-in period into Treatment Period 1 will not be allowed if any of the following applies:

  1. Admitted to the hospital due to asthma exacerbation during the run-in period.
  2. Had upper or lower respiratory tract infection during the 2 weeks just before Visit 2.
  3. Used prohibited drugs during the 2 weeks just before Visit 2.
  4. Is not eligible for the study in the investigator's/subinvestigator's judgment.

Exclusion Criteria for Entry in Treatment Period 2

Enrolment of a subject completing the into Treatment Period 2 will not be allowed if any of the following applies:

  1. Admitted to the hospital due to asthma exacerbation during the washout period.
  2. Had upper or lower respiratory tract infection during the 2 weeks just before Visit 4.
  3. Used prohibited drugs during the 2 weeks just before Visit 4.
  4. Is not eligible for entry in Treatment Period 2 in the investigator's/subinvestigator's judgment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    SLM+FP First

    SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).

    Drug: GW815SF HFA MDI · Drug: salmeterol and fluticasone propionate

  • Active comparator
    SFC First

    SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).

    Drug: GW815SF HFA MDI · Drug: salmeterol and fluticasone propionate

  • Experimental
    SFC

    SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).

    Drug: GW815SF HFA MDI

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods

    Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period \[Weeks 1-4/Weeks 7-10\]).

    Time frame: Crossover Period Weeks 1-4, and 7-10

Secondary outcomes

  1. Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods

    Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

    Time frame: Crossover Period Weeks 1-4, 7-10

  2. Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods

    Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

    Time frame: Crossover Period weeks 1-4, 7-10

  3. Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods

    Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

    Time frame: Crossover Period weeks 1-4, 7-10

  4. Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods

    Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

    Time frame: Crossover Period Weeks 1-4, 7-10

  5. Percentage of Subjects With Symptom-Free Nights & Days

    Percentage of subjects with Symptom Free Nights \& Days after 4 weeks of Treatment

    Time frame: Crossover Period Week 1-4, 7-10

  6. Percentage of Subjects With Rescue Medication-Free Nights and Days

    Percentage of subjects with Rescue Medication Free Nights \& Days after 4 weeks of Treatment

    Time frame: Crossover Period Weeks 1-4, 7-10

  7. Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period

    Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).

    Time frame: Extension Period Weeks 11-30

  8. Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period

    Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

    Time frame: Extension Period weeks 11-30

  9. Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period

    Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

    Time frame: Extension Period weeks 11-30

  10. Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period

    Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

    Time frame: Extension Period weeks 11-30

  11. Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period

    Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

    Time frame: Extension Period weeks 11-30

  12. Percentage of Subjects With Symptom-Free Nights & Days After 20 Weeks of Treatment

    Percentage of subjects with Symptom Free Nights \& Days after 20 weeks of Treatment (at week 30).

    Time frame: Extension Period Weeks 11-30

  13. Percentage of Subjects With Rescue Medication-Free Nights & Days After 20 Weeks of Treatment

    Percentage of subjects with Rescue Medication Free Nights \& Days after 20 weeks of Treatment (at week 30).

    Time frame: Extension Period Weeks 11-30

07

Results

Posted Aug 11, 2009

Participant flow

Treatment Period I - 4 Weeks
Participant flow — Treatment Period I - 4 Weeks
MilestoneSFC 50/100 Mcg/Day FirstSLM 50 Mcg + FP 100 Mcg/Day First
Started2625
Completed2625
Not completed00
Washout Period - 2 Weeks
Participant flow — Washout Period - 2 Weeks
MilestoneSFC 50/100 Mcg/Day FirstSLM 50 Mcg + FP 100 Mcg/Day First
Started2625
Completed2525
Not completed10
Withdrew: Withdrawal by subject10
Treatment Period II - 4 Weeks
Participant flow — Treatment Period II - 4 Weeks
MilestoneSFC 50/100 Mcg/Day FirstSLM 50 Mcg + FP 100 Mcg/Day First
Started2525
Completed2525
Not completed00
Extension Period - 20 Weeks
Participant flow — Extension Period - 20 Weeks
MilestoneSFC 50/100 Mcg/Day FirstSLM 50 Mcg + FP 100 Mcg/Day First
Started500
Completed500
Not completed00

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period \[Weeks 1-4/Weeks 7-10\]).

Time frame:
Crossover Period Weeks 1-4, and 7-10
Reported as:
Mean · Liters/minute
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods
Liters/minuteSFC 50/100 Mcg/DaySLM 50 Mcg + FP 100 Mcg/Day
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods14.3 ± 4.5317.1 ± 4.53
Statistical analysis
  • SFC 50/100 Mcg/Day vs SLM 50 Mcg + FP 100 Mcg/Day · Mixed Models Analysis · p = 0.6383 (Confidence Interval) · Mean difference (net): 2.8 · 95% CI -9.10 to 14.69
SecondaryAdjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

Time frame:
Crossover Period Weeks 1-4, 7-10
Reported as:
Mean · Percentage of predicted value
Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods
Percentage of predicted valueSFC 50/100 Mcg/DaySLM 50 Mcg + FP 100 Mcg/Day
Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods5.38 ± 1.5436.73 ± 1.543
SecondaryAdjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

Time frame:
Crossover Period weeks 1-4, 7-10
Reported as:
Mean · Percentage of personal best value
Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods
Percentage of personal best valueSFC 50/100 Mcg/DaySLM 50mcg + FP 100 Mcg/Day
Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods5.01 ± 1.4806.46 ± 1.480
SecondaryAdjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

Time frame:
Crossover Period weeks 1-4, 7-10
Reported as:
Mean · L/min
Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods
L/minSFC 50/100 Mcg/DaySLM 50 Mcg + FP 100 Mcg/Day
Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods16.3 ± 3.7415.8 ± 3.74
SecondaryAdjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

Time frame:
Crossover Period Weeks 1-4, 7-10
Reported as:
Mean · Percentage of circadian variation
Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods
Percentage of circadian variationSFC 50/100 Mcg/DaySLM 50 Mcg + FP 100 Mcg/Day
Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods0.06 ± 0.638-0.08 ± 0.638
SecondaryPercentage of Subjects With Symptom-Free Nights & Days

Percentage of subjects with Symptom Free Nights \& Days after 4 weeks of Treatment

Time frame:
Crossover Period Week 1-4, 7-10
Reported as:
Number · Percent of participants
Percentage of Subjects With Symptom-Free Nights & Days
Percent of participantsSFC 50/100 Mcg/DaySLM 50 Mcg + FP 100 Mcg/Day
Baseline72.981.3
After 4 Weeks of Treatment91.781.3
SecondaryPercentage of Subjects With Rescue Medication-Free Nights and Days

Percentage of subjects with Rescue Medication Free Nights \& Days after 4 weeks of Treatment

Time frame:
Crossover Period Weeks 1-4, 7-10
Reported as:
Number · Percentage of participants
Percentage of Subjects With Rescue Medication-Free Nights and Days
Percentage of participantsSFC 50/100 Mcg/DaySLM 50 Mcg + FP 100 Mcg/Day
Baseline87.587.5
After 4 Weeks of Treatment93.887.5
SecondaryAdjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).

Time frame:
Extension Period Weeks 11-30
Reported as:
Mean · L/min
Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period
L/minSFC 50/100 Mcg/Day
Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period3.0 ± 24.56
SecondaryAdjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

Time frame:
Extension Period weeks 11-30
Reported as:
Mean · Percentage of predicted value
Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period
Percentage of predicted valueSFC 50/100 Mcg/Day
Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period1.46 ± 9.568
SecondaryAdjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

Time frame:
Extension Period weeks 11-30
Reported as:
Mean · Percentage of personal best value
Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period
Percentage of personal best valueSFC 50/100 Mcg/Day
Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period1.29 ± 8.541
SecondaryAdjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

Time frame:
Extension Period weeks 11-30
Reported as:
Mean · L/Min
Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period
L/MinSFC 50/100 Mcg/Day
Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period2.7 ± 23.43
SecondaryAdjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

Time frame:
Extension Period weeks 11-30
Reported as:
Mean · Percentage of circadian variation
Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period
Percentage of circadian variationSFC 50/100 Mcg/Day
Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period-0.37 ± 3.568
SecondaryPercentage of Subjects With Symptom-Free Nights & Days After 20 Weeks of Treatment

Percentage of subjects with Symptom Free Nights \& Days after 20 weeks of Treatment (at week 30).

Time frame:
Extension Period Weeks 11-30
Reported as:
Number · Percentage of participants
Percentage of Subjects With Symptom-Free Nights & Days After 20 Weeks of Treatment
Percentage of participantsSFC 50/100 Mcg/Day
Baseline84.0
After 20 weeks of treatment (at week 30)84.8
SecondaryPercentage of Subjects With Rescue Medication-Free Nights & Days After 20 Weeks of Treatment

Percentage of subjects with Rescue Medication Free Nights \& Days after 20 weeks of Treatment (at week 30).

Time frame:
Extension Period Weeks 11-30
Reported as:
Number · Percentage of participants
Percentage of Subjects With Rescue Medication-Free Nights & Days After 20 Weeks of Treatment
Percentage of participantsSFC 50/100 Mcg/Day
Baseline90.0
After 20 weeks of treatment (at week 30)89.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SFC 50/100 Mcg/Day—0/51 (0%)12/51 (23.5%)
SLM 50 + FP 100 Mcg/Day—0/50 (0%)10/50 (20%)
SFC 50/100mcg/Day (Extension Period)—0/51 (0%)35/51 (68.6%)
Most frequent other events
Most frequent other events
EventSFC 50/100 Mcg/DaySLM 50 + FP 100 Mcg/DaySFC 50/100mcg/Day (Extension Period)
Upper Respiratory Tract inflammationRespiratory, thoracic and mediastinal disorders7/513/5017/50
NasopharyngitisInfections and infestations2/514/507/50
GastroenteritisInfections and infestations1/512/507/50
AsthmaRespiratory, thoracic and mediastinal disorders1/511/505/50
EczemaSkin and subcutaneous tissue disorders0/510/504/50
StomatitisGastrointestinal disorders2/510/503/50

Baseline characteristics

Age Continuous
Age Continuous(Years)Overall Study Population
Mean8.3 ± 2.41
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Population
Female17
Male34
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall Study Population
Asian-Japanese Heritage51
Region of Enrollment
Region of Enrollment(participants)Overall Study Population
Japan51
08

Study locations

8 sites
  • GSK Investigational Site
    Chiba, 260-0001, Japan
  • GSK Investigational Site
    Kanagawa, 245-0018, Japan
  • GSK Investigational Site
    Saitama, 360-0018, Japan
  • GSK Investigational Site
    Saitama, 360-0812, Japan
  • GSK Investigational Site
    Tokyo, 154-0002, Japan
  • GSK Investigational Site
    Tokyo, 154-0017, Japan
  • GSK Investigational Site
    Tokyo, 158-0083, Japan
  • GSK Investigational Site
    Tokyo, 158-0097, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2007
First posted
Mar 16, 2007
Start
Apr 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Aug 11, 2009
Last update
Jun 8, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00448435
Lead sponsor
GlaxoSmithKline
First posted
Mar 16, 2007
Start date
Apr 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Aug 11, 2009
Last update
Jun 8, 2010

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone

Start the discussion